Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


Articles published in Cancer Res

Retrieve available abstracts of 60 articles:
HTML format
Text format



Single Articles


    March 2017
  1. MIAO L, Yang L, Li R, Nava Rodrigues D, et al
    Disrupting androgen receptor signaling induces Snail-mediated epithelial-mesenchymal plasticity in prostate cancer.
    Cancer Res. 2017 Mar 16. pii: canres.2169.2016.
    PubMed     Text format     Abstract available


    February 2017
  2. THOMAS JD, Longen CG, Oyer HM, Chen N, et al
    Sigma1 Targeting to Suppress Aberrant Androgen Receptor Signaling in Prostate Cancer.
    Cancer Res. 2017 Feb 24. pii: canres.1055.2016.
    PubMed     Text format     Abstract available


  3. ZHANG K, Guo Y, Wang X, Zhao H, et al
    WNT/beta-catenin directs self-renewal symmetric cell division of hTERThigh prostate cancer stem cells.
    Cancer Res. 2017 Feb 16. pii: canres.1887.2016.
    PubMed     Text format     Abstract available


  4. MINCIACCHI VR, Spinelli C, Reis-Sobreiro M, Cavallini L, et al
    MYC mediates large oncosome-induced fibroblast reprogramming in prostate cancer.
    Cancer Res. 2017 Feb 15. pii: canres.2942.2016.
    PubMed     Text format     Abstract available


    January 2017
  5. ALFAQIH MA, Nelson ER, Liu W, Safi R, et al
    CYP27A1 loss dysregulates cholesterol homeostasis in prostate cancer.
    Cancer Res. 2017 Jan 27. pii: canres.2738.2016.
    PubMed     Text format     Abstract available


  6. VAN OORSCHOT B, Uitterhoeve L, Oomen I, Ten Cate R, et al
    Prostate cancer patients with late radiation toxicity exhibit reduced expression of genes involved in DNA double strand break repair and homologous recombination.
    Cancer Res. 2017 Jan 20. pii: canres.1966.2016.
    PubMed     Text format     Abstract available


  7. NANDANA S, Tripathi M, Duan P, Chu CY, et al
    Bone metastasis of prostate cancer can be therapeutically targeted at the TBX2-WNT signaling axis.
    Cancer Res. 2017 Jan 20. pii: canres.0497.2016.
    PubMed     Text format     Abstract available


    December 2016
  8. DAS R, Gregory PA, Fernandes RC, Denis I, et al
    MicroRNA-194 promotes prostate cancer metastasis by inhibiting SOCS2.
    Cancer Res. 2016 Dec 23. pii: canres.2529.2016.
    PubMed     Text format     Abstract available


  9. THANGAVEL C, Boopathi E, Liu Y, Haber A, et al
    RB loss promotes prostate cancer metastasis.
    Cancer Res. 2016 Dec 6. pii: canres.1589.2016.
    PubMed     Text format     Abstract available


    November 2016
  10. CHOUDHURY AD, Schinzel AC, Cotter MB, Lis RT, et al
    Castration resistance in prostate cancer is mediated by the kinase NEK6.
    Cancer Res. 2016 Nov 29. pii: canres.0455.2016.
    PubMed     Text format     Abstract available


  11. AUDET-WALSH E, Yee T, McGuirk S, Vernier M, et al
    Androgen-dependent repression of ERRgamma reprograms metabolism in prostate cancer.
    Cancer Res. 2016 Nov 7. pii: canres.1204.2016.
    PubMed     Text format     Abstract available


  12. FONG KW, Zhao JC, Kim J, Li S, et al
    Polycomb-mediated disruption of an androgen receptor feedback loop drives castration-resistant prostate cancer.
    Cancer Res. 2016 Nov 4. pii: canres.1949.2016.
    PubMed     Text format     Abstract available


  13. GELMAN IH
    How the TRAMP Model Revolutionized the Study of Prostate Cancer Progression.
    Cancer Res. 2016;76:6137-6139.
    PubMed     Text format    


    October 2016
  14. DAY KC, Lorenzatti Hiles G, Kozminsky M, Dawsey SJ, et al
    HER2 and EGFR overexpression support metastatic progression of prostate cancer to bone.
    Cancer Res. 2016 Oct 28. pii: canres.1656.2016.
    PubMed     Text format     Abstract available


    September 2016
  15. VARZAVAND A, Hacker W, Ma D, Gibson-Corley KN, et al
    alpha3beta1 Integrin suppresses prostate cancer metastasis via regulation of the Hippo pathway.
    Cancer Res. 2016 Sep 28. pii: canres.1483.2016.
    PubMed     Text format     Abstract available


  16. XIE M, Vesuna F, Tantravedi S, Bol GM, et al
    RK-33 radiosensitizes prostate cancer cells by blocking the RNA helicase DDX3.
    Cancer Res. 2016 Sep 12. pii: canres.0440.2016.
    PubMed     Text format     Abstract available


    August 2016
  17. ZHANG L, Wang J, Wang Y, Zhang Y, et al
    MNX1 is oncogenically upregulated in African-American prostate cancer.
    Cancer Res. 2016 Aug 30. pii: canres.0087.2016.
    PubMed     Text format     Abstract available


  18. WANG Y, Dehigaspitiya DC, Levine PM, Profit AA, et al
    Multivalent peptoid conjugates suppress enzalutamide-resistant prostate cancer cellular proliferation.
    Cancer Res. 2016 Aug 3. pii: canres.0385.2016.
    PubMed     Text format     Abstract available


  19. TSAI CH, Tzeng SF, Chao TK, Tsai CY, et al
    Metastatic progression of prostate cancer is mediated by autonomous binding of galectin-4-O-glycan to cancer cells.
    Cancer Res. 2016 Aug 2. pii: canres.0641.2016.
    PubMed     Text format     Abstract available


    July 2016
  20. LU H, Wang T, Li J, Fedele C, et al
    alphavbeta6 Integrin Promotes Castrate-Resistant Prostate Cancer Through JNK1-Mediated Activation of Androgen Receptor.
    Cancer Res. 2016 Jul 22. pii: canres.0543.2016.
    PubMed     Text format     Abstract available


    June 2016
  21. STOPSACK KH, Gerke TA, Sinnott JA, Penney KL, et al
    Cholesterol metabolism and prostate cancer lethality.
    Cancer Res. 2016 Jun 20. pii: canres.0903.2016.
    PubMed     Text format     Abstract available


  22. YOU S, Knudsen BS, Erho N, Alshalalfa M, et al
    Integrated classification of prostate cancer reveals a novel luminal subtype with poor outcome.
    Cancer Res. 2016 Jun 14. pii: canres.0902.2016.
    PubMed     Text format     Abstract available


    May 2016
  23. SHEIKH NA, Cham J, Zhang L, DeVries T, et al
    Clonotypic Diversification of Intratumoral T Cells Following Sipuleucel-T Treatment in Prostate Cancer Subjects.
    Cancer Res. 2016 May 23. pii: canres.3173.2015.
    PubMed     Text format     Abstract available


  24. SATO S, Katsushima K, Shinjo K, Hatanaka A, et al
    Histone deacetylase inhibition in prostate cancer triggers miR-320-mediated suppression of the androgen receptor.
    Cancer Res. 2016 May 23. pii: canres.3339.2015.
    PubMed     Text format     Abstract available


  25. ALBINO D, Civenni G, Dallavalle C, Roos M, et al
    Activation of the Lin28/let7 axis by loss of ESE3/EHF promotes a tumorigenic and stem-like phenotype in prostate cancer.
    Cancer Res. 2016 May 2. pii: canres.2665.2015.
    PubMed     Text format     Abstract available


  26. FERRALDESCHI R, Welti J, Powers MV, Yuan W, et al
    Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells.
    Cancer Res. 2016;76:2731-2742.
    PubMed     Text format     Abstract available


    April 2016
  27. PASERO C, Gravis G, Guerin M, Granjeaud S, et al
    Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity.
    Cancer Res. 2016;76:2153-65.
    PubMed     Text format     Abstract available


  28. YU X, Wang H, Li X, Guo C, et al
    Activation of the MDA-5-IPS-1 Viral Sensing Pathway Induces Cancer Cell Death and Type I IFN-Dependent Antitumor Immunity.
    Cancer Res. 2016;76:2166-76.
    PubMed     Text format     Abstract available


    March 2016
  29. PEITZSCH C, Cojoc M, Hein L, Kurth I, et al
    An epigenetic reprogramming strategy to re-sensitize radioresistant prostate cancer cells.
    Cancer Res. 2016 Mar 16. pii: canres.2116.2015.
    PubMed     Text format     Abstract available


  30. PRUEITT RL, Wallace TA, Glynn SA, Yi M, et al
    An Immune-Inflammation Gene Expression Signature in Prostate Tumors of Smokers.
    Cancer Res. 2016;76:1055-65.
    PubMed     Text format     Abstract available


  31. BILIR B, Osunkoya AO, Wiles WG 4th, Sannigrahi S, et al
    SOX4 Is Essential for Prostate Tumorigenesis Initiated by PTEN Ablation.
    Cancer Res. 2016;76:1112-21.
    PubMed     Text format     Abstract available


  32. ARGYROS O, Karampelas T, Asvos X, Varela A, et al
    Peptide-Drug Conjugate GnRH-Sunitinib Targets Angiogenesis Selectively at the Site of Action to Inhibit Tumor Growth.
    Cancer Res. 2016;76:1181-92.
    PubMed     Text format     Abstract available


    February 2016
  33. MIFTAKHOVA R, Hedblom A, Semenas J, Robinson BD, et al
    Cyclin A1 and P450 aromatase promote metastatic homing and growth of stem-like prostate cancer cells in the bone marrow.
    Cancer Res. 2016 Feb 26. pii: canres.2340.2015.
    PubMed     Text format     Abstract available


  34. TRAVIS RC, Appleby PN, Martin RM, Holly JM, et al
    A meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate cancer risk.
    Cancer Res. 2016 Feb 26. pii: canres.1551.2015.
    PubMed     Text format     Abstract available


  35. LINN DE, Penney KL, Bronson RT, Mucci LA, et al
    Deletion of interstitial genes between TMPRSS2 and ERG promotes prostate cancer progression.
    Cancer Res. 2016 Feb 15. pii: canres.1911.2015.
    PubMed     Text format     Abstract available


  36. NAKAJIMA K, Kho DH, Yanagawa T, Harazono Y, et al
    Galectin-3 cleavage alters bone remodeling: Different outcomes in breast and prostate cancer skeletal metastasis.
    Cancer Res. 2016 Feb 2. pii: canres.1793.2015.
    PubMed     Text format     Abstract available


    January 2016
  37. YAN J, Ojo D, Kapoor A, Lin X, et al
    Neural cell adhesion protein CNTN1 promotes the metastatic progression of prostate cancer.
    Cancer Res. 2016 Jan 21. pii: canres.1898.2015.
    PubMed     Text format     Abstract available


  38. NELSON WG
    Commentary on Huggins and Hodges: "Studies on Prostatic Cancer".
    Cancer Res. 2016;76:186-7.
    PubMed     Text format    


  39. LI N, Dhar SS, Chen TY, Kan PY, et al
    JARID1D is a suppressor and prognostic marker of prostate cancer invasion and metastasis.
    Cancer Res. 2016 Jan 8. pii: canres.0906.2015.
    PubMed     Text format     Abstract available


    December 2015
  40. MARTIN SK, Pu H, Penticuff JC, Cao Z, et al
    Multinucleation and mesenchymal-to-epithelial transition alleviate resistance to combined cabazitaxel and antiandrogen therapy in advanced prostate cancer.
    Cancer Res. 2015 Dec 8. pii: canres.2078.2015.
    PubMed     Text format     Abstract available


    November 2015
  41. CASIMIRO MC, Di Sante G, Ju X, Li Z, et al
    Cyclin D1 promotes androgen-dependent DNA damage repair in prostate cancer cells.
    Cancer Res. 2015 Nov 18. pii: canres.0999.2015.
    PubMed     Text format     Abstract available


  42. SHI XB, Ma A, Xue L, Li M, et al
    miR-124 and androgen receptor signaling inhibitors repress prostate cancer growth by downregulating androgen receptor splice variants, EZH2 and Src.
    Cancer Res. 2015 Nov 16. pii: canres.0795.2014.
    PubMed     Text format     Abstract available


  43. TA HQ, Ivey ML, Frierson HF Jr, Conaway MR, et al
    Checkpoint Kinase 2 Negatively Regulates Androgen Sensitivity and Prostate Cancer Cell Growth.
    Cancer Res. 2015.
    PubMed     Text format     Abstract available


  44. SPRATT DE, Evans MJ, Davis BJ, Doran MG, et al
    Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation.
    Cancer Res. 2015;75:4688-96.
    PubMed     Text format     Abstract available


  45. HUBBARD GK, Mutton LN, Khalili M, McMullin RP, et al
    Combined MYC activation and Pten loss are sufficient to create genomic instability and lethal metastatic prostate cancer.
    Cancer Res. 2015 Nov 10. pii: canres.3280.2014.
    PubMed     Text format     Abstract available


  46. LEE YC, Lin SC, Yu G, Cheng CJ, et al
    Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer.
    Cancer Res. 2015.
    PubMed     Text format     Abstract available


    October 2015
  47. HURLEY PJ, Hughes RM, Simons BW, Huang J, et al
    Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression.
    Cancer Res. 2015;75:4322-34.
    PubMed     Text format     Abstract available


  48. WANG M, Kimbrell HZ, Sholl AB, Tulman DB, et al
    High-Resolution Rapid Diagnostic Imaging of Whole Prostate Biopsies Using Video-Rate Fluorescence Structured Illumination Microscopy.
    Cancer Res. 2015;75:4032-41.
    PubMed     Text format     Abstract available


    September 2015
  49. BERNARDO MM, Kaplun A, Dzinic SH, Li X, et al
    Maspin Expression in Prostate Tumor Cells Averts Stemness and Stratifies Drug Sensitivity.
    Cancer Res. 2015;75:3970-9.
    PubMed     Text format     Abstract available


  50. XU D, Zhan Y, Qi Y, Cao B, et al
    Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes.
    Cancer Res. 2015;75:3663-71.
    PubMed     Text format     Abstract available


    August 2015
  51. YLIPAA A, Kivinummi K, Kohvakka A, Annala M, et al
    Transcriptome sequencing reveals PCAT5 as a novel ERG-regulated long non-coding RNA in prostate cancer.
    Cancer Res. 2015 Aug 17. pii: canres.0217.2015.
    PubMed     Text format     Abstract available


    July 2015
  52. BOWEN C, Zheng T, Gelmann EP
    NKX3.1 Suppresses TMPRSS2-ERG Gene Rearrangement and Mediates Repair of Androgen Receptor-Induced DNA Damage.
    Cancer Res. 2015;75:2686-98.
    PubMed     Text format     Abstract available


    June 2015
  53. CHANG YS, Chen WY, Yin JJ, Tillman H, et al
    EGF receptor promotes prostate cancer bone metastasis by downregulating miR-1 and activating TWIST1.
    Cancer Res. 2015 Jun 12. pii: canres.3380.2014.
    PubMed     Text format     Abstract available


  54. CERASUOLO M, Paris D, Iannotti FA, Melck D, et al
    Neuroendocrine Transdifferentiation in Human Prostate Cancer Cells: An Integrated Approach.
    Cancer Res. 2015 Jun 11. pii: canres.3830.2014.
    PubMed     Text format     Abstract available


    May 2015
  55. KO CJ, Huang CC, Lin HY, Juan CP, et al
    Androgen-induced TMPRSS2 activates matriptase and promotes extracellular matrix degradation, prostate cancer cell invasion, tumor growth and metastasis.
    Cancer Res. 2015 May 27. pii: canres.3297.2014.
    PubMed     Text format     Abstract available


  56. JACHETTI E, Caputo S, Mazzoleni S, Brambillasca CS, et al
    Tenascin-C Protects Cancer Stem-like Cells from Immune Surveillance by Arresting T-cell Activation.
    Cancer Res. 2015;75:2095-108.
    PubMed     Text format     Abstract available


  57. CHEN K, Wu K, Jiao X, Wang L, et al
    The endogenous cell-fate factor dachshund restrains prostate epithelial cell migration via repression of cytokine secretion via a cxcl signaling module.
    Cancer Res. 2015;75:1992-2004.
    PubMed     Text format     Abstract available


    April 2015
  58. LIU R, Yi B, Wei S, Yang WH, et al
    FOXP3-miR-146-NF-kappaB Axis and Therapy for Precancerous Lesions in Prostate.
    Cancer Res. 2015;75:1714-24.
    PubMed     Text format     Abstract available


  59. BROWN M, Chinnaiyan A, Farsetti A, Livingston DM, et al
    26th Pezcoller symposium: cancers driven by hormones.
    Cancer Res. 2015;75:1177-80.
    PubMed     Text format     Abstract available


  60. FOX JL, Storey A
    BMX Negatively Regulates BAK Function, Thereby Increasing Apoptotic Resistance to Chemotherapeutic Drugs.
    Cancer Res. 2015;75:1345-55.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: